In April 2020, selumetinib, an oral selective MEK inhibitor was approved by the US Food and Drug Administration for the treatment of children with NF1-related symptomatic, progressive, inoperable plexiform neurofibroma, which can also be effective in the treatment of optic glioma [17,18]. This evidence concerns the gene MAP2K7 and plexiform neurofibroma.